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A Case of EVALI from Vaping Marijuana
Charles Hammond MD and Alexis Haftka-George MD
Henry Ford Health System, Detroit, Michigan
Introduction

CT Chest with Contrast on Presentation

E-cigarette use or “vaping” has become a popular alternative to cigarette
smoking. As a result, the CDC noted a significant increase beginning in March
2019 of patients hospitalized with acute lung injury in the setting of recent ecigarette use and classified this condition as E-cigarette or vaping product use
associated lung injury (EVALI). As of February 18th 2020, there have been 2807
EVALI-related hospitalizations and 69 deaths reported to the CDC1.

As illustrated in this case, EVALI can be a very rapidly progressive and
severe disease process. In one review of 60 patients who presented with
EVALI, 55% were admitted to the intensive care unit.4 Given the rapid
progression and severity of the disease, establishing a way to detect and
promptly treat EVALI is very important.
As a result of the increased incidence of EVALI, the CDC recommends
anyone with signs of symptoms of a pulmonary illness be asked if they
used an e-cigarette within the last 90 days.5 Typical symptoms of EVALI
include both shortness of breath as well as abdominal pain and diarrhea,
as exhibited in our patient.
Inpatient management generally consists of glucorticoids and antibiotics
to cover CAP. Duration of steroid treatment has not been definitively
established. In this case, we see that after 5 days of glucocorticoids there
was significant improvement in the patient’s respiratory function, and
within one week of steroid initiation she improved from ventilatordependence to being discharged home on room air.

The clinical presentation for EVALI typically consists of lower respiratory tract
and gastrointestinal symptoms. Treatment typically consists of glucorticoids and
supportive care, although duration of treatment and clinical course is variable on
a case-by-case basis. The exact pathophysiology for the lung injury has not been
completely explained, but it is thought to be related to some specific toxins in the
e-cigarettes including vitamin E acetate, THC, various hydrocarbons and some
silicon-conjugated compounds.2 A recent study from Wisconsin reported that
even at four to five weeks after discharge there was residual diffusion
abnormalities in the patients hospitalized for EVALI.3

Case Presentation
A 25 year old female presented with acute-onset chest pain and shortness of
breath. She reported associated abdominal pain, nausea and diarrhea. Initial
workup in the emergency department revealed tachycardia to 140bpm but she was
afebrile. Laboratory workup revealed leukocytosis and a CT scan of the chest
revealed multifocal pneumonia (Figure 1). While in the emergent department,
although not hypoxic at rest she desaturated to 89% on room air with ambulation.
She was started on ceftriaxone and azithromycin and was admitted to the general
medical unit for community-acquired pneumonia.
On hospital day two she became more dyspneic and had progressive hypoxia,
eventually saturating only 90% on six liters nasal cannula. At this time, upon
taking further social history, it was discovered that she regularly vaped marijuana
for anxiety, with the last use being six days prior to presentation. On hospital day
three she was intubated for acute hypoxic respiratory failure, her antibiotics were
escalated to vancomycin, cefepime and azithromycin and she was transferred to
the ICU.
In the intensive care unit she was started on steroids for EVALI treatment,
initially with methylprednisolone 1mg/kg IV daily. She required paralytics due to
being asynchronous with the ventilator. On hospital day five she was proned to
help with her oxygenation, and remained so for approximately thirty-six hours.
On hospital day eight she was successfully extubated and on hospital day nine she
was transferred to the GPU on one liter nasal cannula. She was discharged home
on room air on hospital day ten and was prescribed a steroid taper to complete a
total of thirteen days of treatment.

Discussion

Figure 1. Radiology read: “Multifocal patchy groundglass and consolidative
opacities in the lungs bilaterally”
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Take Home Points
1. Any patient presenting with a pulmonary illness should be asked about
previous use of e-cigarettes or vaping
2. Gastrointestinal symptoms are common in EVALI
3. EVALI can be rapidly progressing, and initiation of glucocorticoids
appears to be beneficial for severe illness manifestations
4. There may be downstream, permanent respiratory dysfunction as a result of
EVALI
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